400-920-2911 sales@csnpharm.cn
Endothelin Receptor
货号 | 产品名 | CAS号 | 信息 |
---|---|---|---|
CSN13675 | Zibotentan | 186497-07-4 | Zibotentan is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). |
CSN29551 | ZD-1611 | 186497-38-1 | ZD1611 is an endothelin receptor antagonist. |
CSN12014 | Sulfisoxazole | 127-69-5 | Sulfisoxazole is an antagonist of endothelin receptor that can be used as a sulfonamide antibacterial agent. |
CSN11008 | Sodium Ferulate | 24276-84-4 | Sodium ferulate is the sodium salt of ferulic acid which is used for the treatment of cardiovascular disease. |
CSN12974 | Sitaxsentan Sodium | 210421-74-2 | Sitaxsentan sodium has selectory antagonism of endothelin A (ETA) receptor with the IC50 and Ki value of 1.4 nM and 0.43 nM respectively. |
CSN12975 | Sitaxsentan | 184036-34-8 | Sitaxsentan is a selective endothelin A (ETA) receptor antagonist. |
CSN24483 | Ro 46-8443 | 175556-12-4 | Ro 46-8443 is the first non-peptide Endothelin Receptor B selective antagonist with IC50 value of 110nM. |
CSN17902 | Ro 46-2005 | 150725-87-4 | Ro 46-2005 is an antagonist of endothelin receptor. |
CSN25744 | IRL-2500 | 169545-27-1 | IRL-2500 is a potent endothelin receptor antagonist with IC50 values of 1.3 and 94 nM for ETB and ETA receptors respectively. |
CSN25742 | Endothelin 2 (human) | 123562-20-9 | Endothelin 2 (human) is endogenous peptide found predominately in the kidney and intestine. Endothelin 2 displays similar selectivity for ETA and ETB endothelin receptors. |
CSN21629 | Endothelin 1 (human, porcine) | 117399-94-7 | Endothelin 1 (human, porcine) is a peptide vasoconstrictor and agonist of endothelin (ET) receptors ETA and ETB. |
CSN23533 | Darusentan | 171714-84-4 | Darusentan is an antagonist of endothelin ETA receptor and it can be used to treat congestive heart failure and hypertension. |
CSN17348 | BQ-788 Sodium | 156161-89-6 | BQ-788 sodium salt is a potent, selective ETB receptor antagonist with IC50 of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC50 of 1300 nM. |
CSN18010 | BQ-788 | 173326-37-9 | BQ-788 is a potent and selective endothelin receptor subtype B (ETB) antagonist with IC50 of 1.2 nM (inhibits 125I-labeled endothelin 1 (ET-1) binding to ETB receptors on human Girardi heart cells). |
CSN17753 | BQ-123 | 136553-81-6 | BQ-123 is a specific antagonist of endothelin A receptor (ETA) and the IC50 is 7.3 nM. |
CSN10481 | Bosentan Hydrate | 157212-55-0 | Bosentan is an endothelin (ET) receptor antagonist of ET-A (Ki = 4.7 nM) and ET-B (Ki = 95 nM). |
CSN10480 | Bosentan | 147536-97-8 | Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively. |
CSN12872 | Avosentan | 290815-26-8 | Avosentan is a potent, selective endothelin receptor (ETA receptor) antagonist. |
CSN23856 | Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate | 1366000-58-9 | Atrial Natriuretic Peptide (1-28), human, porcine Acetate is a 28-amino acid hormone, it is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. It inhibits endothelin-1 secretion in a dose-dependent way. |
CSN18015 | Atrasentan | 173937-91-2 | Atrasentan is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
CSN13753 | Atrasentan HCl | 195733-43-8 | Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
CSN10496 | Ambrisentan | 177036-94-1 | Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A receptor (IC50s = 0.251, 0.316, 0.398, 251, and 630 nM for rat preparations of heart, bladder, kidney, lung, and cerebral cortex, respectively). |
CSN25741 | A 127722 | 195704-72-4 | A 127722 is a potent ETA endothelin receptor antagonist with IC50 values of 0.11 nM and 98 nM for human ETA and ETB receptors, respectively. |